Teicoplanin

Names

[ Name ]:
Teicoplanin

[Synonym ]:
teichomycin
TEICOPLANIN
(1S,2R,19R,22R,34S,37R,40R,52R)-2-[(2-Acetamido-2-deoxy-β-D-glucopyranosyl)oxy]-22-amino-5,15-dichloro-64-{[2-(decanoylamino)-2-deoxy-β-D-glucopyranosyl]oxy}-26,31,44,49-tetrahydroxy-47-(α-D -mannopyranosyloxy)-21,35,38,54,56,59-hexaoxo-7,13,28-trioxa-20,36,39,53,55,58-hexaazaundecacyclo[38.14.2.2.2.2.1.1.1.1.0.0]hexahexaconta-3, 5,8(64),9,11,14,16,23(61),24,26,29(60),30,32
TEICOPLANIN,JP
Tagocid
TeicoplaninSodium
8327a
TEIC
Teicoplanin(sterile,non-sterile)
antibiotic8327a
Teocoplanin

Biological Activity

[Description]:

Teicoplanin is a semisynthetic glycopeptide antibiotic used in the prophylaxis and treatment of serious infections caused by Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Enterococcus faecalis.

[Related Catalog]:

Signaling Pathways >> Anti-infection >> Bacterial

Research Areas >> Infection

[Related Small Molecules]

Chemical & Physical Properties

[ Density]:
1.7±0.1 g/cm3

[ Molecular Formula ]:
C₁₃₀H₁₇₅Cl₂N₉O₃₇R₆

[ Molecular Weight ]:
2526.73

[ PSA ]:
662.41000

[ LogP ]:
0.40

[ Index of Refraction ]:
1.754

[ Storage condition ]:
2-8℃

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: WY1559000

CHEMICAL NAME :: Teicoplanin

CAS REGISTRY NUMBER :: 61036-62-2

LAST UPDATED :: 198910

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 14 mg/kg/31D-I

TOXIC EFFECTS :: Sense Organs and Special Senses (Ear) - change in acuity

REFERENCE :: LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823- Volume(issue)/page/year: 1,613,1986

Safety Information

[ Personal Protective Equipment ]:
Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter

[ Hazard Codes ]:
Xi

[ RIDADR ]:
NONH for all modes of transport

[ RTECS ]:
WY1559000

Articles

Role of extra-cellular fatty acids in vancomycin induced biofilm formation by vancomycin resistant Staphylococcus aureus.

Pak. J. Pharm. Sci. 26(2) , 383-9, (2013)

In the present study a vancomycin resistant Staphylococcus aureus (S. aureus) (VRSA) (Labeled as CP2) was isolated from the blood of a post-operative cardiac patient is described. It harbors a plasmid...

A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity.

Sci. Transl. Med. 7 , 290ra89, (2015)

Currently, no approved therapeutics exist to treat or prevent infections induced by Ebola viruses, and recent events have demonstrated an urgent need for rapid discovery of new treatments. Repurposing...

Once-weekly dalbavancin versus daily conventional therapy for skin infection.

N. Engl. J. Med. 370(23) , 2169-79, (2014)

Dalbavancin, a lipoglycopeptide antibiotic agent that is active against gram-positive pathogens, has a long plasma half-life, allowing for once-weekly dosing. DISCOVER 1 and DISCOVER 2 were identicall...